Exciting things are happening every day at VCU Massey Cancer Center. We’re saving lives and reducing suffering from cancer. We’re discovering new and better ways to prevent, diagnose and treat cancer. We’re offering opportunities for the community to join us in the progress against cancer.
Updates to outpatient care at Massey due to COVID-19
At VCU Massey Cancer Center we have implemented changes in our clinics to mitigate the coronavirus (COVID-19) situation and keep our patients and medical teams safe.
Today, the American Association of Cancer Research (AACR) released its inaugural Cancer Disparities Progress Report, which outlines the enormous toll that cancer exacts on racial and ethnic minorities and other underserved populations, highlights areas of progress in reducing these disparities and provides specific recommendations for achieving health equity. As a member of the AACR Steering Committee that contributed to the report, VCU Massey Cancer Center Director Robert Winn, M.D., was part of a virtual Congressional briefing on the findings.
VCU Massey Cancer Center researcher Nicholas Farrell, Ph.D., received the University Award of Excellence during VCU’s annual Faculty Convocation ceremony on September 10. VCU President Michael Rao, Ph.D., acknowledged that the six faculty members honored with various awards during the ceremony embody the university’s mission and are actively working to transform lives, despite the challenges facing the university and the nation.
National clinical trial open at Massey will examine short- and long-term outcomes of patients with COVID-19 and cancer
A nationwide clinical trial funded by the National Cancer Institute and now open at VCU Massey Cancer Center will examine the short- and long-term outcomes of patients with COVID-19 and cancer to gain a more comprehensive understanding of the impacts of infection. The NCI COVID-19 in Cancer Patients Study (N-CCaPS) is a longitudinal natural history study that will include a national registry of blood samples and radiologic images from adult cancer patients infected with the novel coronavirus to analyze disease pathology.
VCU Massey Cancer Center researcher Larisa Litovchick, M.D., Ph.D., was recently awarded $465,000 from the National Institute of Dental and Cranial Research to further investigate how human papillomavirus (HPV) leads to head and neck cancers. Findings may aid the development of novel targeted treatments.
In his previous role at Moffitt Cancer Center, Said Sebti, Ph.D., the associate director for basic research at VCU Massey Cancer Center, and his collaborators discovered a novel drug called FGTI-2734 that overcomes a major hurdle in halting the growth of malignant tumors driven by the cancer-causing KRAS protein, including pancreatic cancer. In collaboration with Massey researchers and the Medicines for All Institute (M4ALL) at VCU, Sebti intends to further develop FGTI-2734 at Massey in an effort to eventually gain FDA approval for testing the drug in clinical trials.